About us.

Matt serves clients within the life science industry on commercial strategy issues. He has led projects that leverage detailed and integrative analytics to inform critical strategic decisions, focused on market opportunity identification (including physician and patient segmentation), product positioning and launch strategies, and customer engagement model design. He has deep expertise in complex hematology/ oncology, immunology, and orphan disease markets, with significant experience in cardiovascular, CNS, and infectious disease markets. He has led multiple internal knowledge development initiatives for the firm, including research on state-of-the art approaches to segmentation, understanding adherence from a business perspective, and integrating clinical and access research to inform comprehensive assessments of market potential. Matt is a guest lecturer at Harvard, MIT, and the Broad Institute. He earned his MBA from the Yale School of Management in Yale’s Healthcare MBA program and his BA in Economics from Boston College.

Emma has deep experience supporting organisations across the utilities, public and private sectors to deliver strategic projects and large-scale transformation programmes. At Inizio Advisory, Emma is responsible for driving all aspects of the Inizio Advisory strategy and bringing initiatives to life. Emma will also oversee the organisation's change programme. Prior to joining Inizio, Emma was a Director of EY's People Consulting business and also held the position of Chief of Staff for Ireland Consulting. Prior to joining EY, Emma also worked with Accenture Management Consulting.

President of Inizio Advisory, Remco leads the Advisory leadership team in facilitating continued growth globally, connecting the organization’s expertise to drive results for clients and create a positive impact on patients. Remco joined Putnam, a strategy consulting firm and part of Inizio Advisory, in 2000, spending the first 12 years as a strategic advisor to a number of top 20 biopharmaceutical companies. After becoming a Partner in 2012, Remco supported the growth of the firm from a small boutique to one of the leading global life science strategy consultancies. In 2019, Remco became the CEO of Putnam and supported the team in driving strong organic growth and managing strategically relevant acquisitions to make the firm what it is today – a strong 400+ team and leading advisory organization for the life sciences. In 2025, Remco became the President of Inizio Advisory. He grew up in the Netherlands and received his Bachelor’s degree in International Management from the Fontys University, Eindhoven and his Master’s degree in International Marketing from the University of Strathclyde in Glasgow, Scotland.

Jeff Dill is the CEO of Vynamic, a leading healthcare industry management consulting company helping innovative clients in the US, UK, and Europe achieve actionable strategy, operational intelligence, and healthy culture. With over 20 years of experience in consulting, Jeff started his career at Accenture and joined Vynamic in 2005 – inspired by their purpose: We Believe There Is A Better Way. Jeff is driven by his professional passion for ‘TACT’ - Transparency, Awareness, Clarity, and Trust - and has used this approach to clear communications to create a better experience for Vynamic team members and the clients they serve. Key elements of the healthy corporate culture Jeff leads have been featured on CNBC and The Wall Street Journal.

With a broad experience in the pharmaceutical industry spanning over more than 25 years, Dermot joined STEM as CEO in November 2021. As CEO, Dermot is responsible for driving growth and innovation within STEM. Prior to joining STEM Dermot spent 5 years at Novartis in the Clinical Development arena, first leading a major transformation in clinical data operations and then leading the broader clinical technology and innovation function. In this role, Dermot had responsibility for the support, oversight and evolution of Novartis’ end to end clinical technology platform and for driving digitization and innovation in the execution of clinical trials.